Articles tagged with: Torisel
News»
Treatment strategies that combine Revlimid with newer types of anti-tumor agents may be effective for relapsed and refractory multiple myeloma, according to myeloma experts who reviewed results from studies of these new combinations.
Refractory and relapsed multiple myeloma is notoriously difficult to treat. For every remission period that is achieved, relapse typically arises sooner and with greater resistance to previously used therapies. These patients have limited options for therapy.
In examining trials that tested new therapies in combination with Revlimid (lenalidomide), the authors of the review hoped to find the potential …
News»
Earlier this year, an international group of myeloma experts published a review of ongoing research into new myeloma treatments. This review not only described a wide range of potential new myeloma treatments, but also included the experts' thoughts on where research into new treatments should go in the future.
Given the recent new drug application for carfilzomib and the upcoming annual meeting of the American Society of Hematology -- which undoubtedly will host discussions of many potential new myeloma treatments -- it seems an appropriate time to go back to the experts' review from …
NewsFlash »
Protein May Interfere With Revlimid Doses In The Body – Results of a recent small Phase 1 clinical trial investigating the efficacy and safety of Revlimid (lenalidomide) in combination with Torisel (temsirolimus) suggest that P-glycoprotein, a protein that causes the removal of certain drugs from cells into the bloodstream, interferes with Revlimid dosing. High levels of P-glycoprotein in cancer cells may be the cause of drug resistance. The researchers observed higher than expected concentrations of Revlimid in the patients’ bloodstreams. Experiments in the lab showed that P-glycoprotein removed Revlimid from the cancer cells. The experiments also showed that the rate of removal was lower when Torisel was added to the experiments, which, according to the study authors, is evidence that the two drugs interact via P-glycoprotein. For more information, please see the study in the Journal of Clinical Oncology (abstract) or the Ohio State University Medical Center press release.
Phase 2 Trial Of Carfilzomib For Multiple Myeloma Is Recruiting Patients – The Multiple Myeloma Clinical Research Section at the National Cancer Institute is recruiting participants for a Phase 2 trial to test the effectiveness of the investigational drug carfilzomib in combination with Revlimid and dexamethasone (Decadron) in newly-diagnosed multiple myeloma patients. Patients will receive eight 28-day treatment cycles. Those who show at least stable disease after the treatment may continue to receive 12 cycles of low-dose Revlimid maintenance therapy. In addition to current standard, clinical methods for determining responses to the drugs, the researchers will use new molecular methods to assess response and to detect minimal residual disease. To participate in the trial, please contact the research nurse, Mary Ann Yancey, at (301) 435-9227 or .
Chicago Area Workshop For Multiple Myeloma Patients – The Multiple Myeloma Research Foundation will hold a one-day educational workshop for myeloma patients and their family members on August 20 in Oak Brook, IL. The program will be led by Dr. Todd Zimmerman, a myeloma expert from the University of Chicago Medical Center. Throughout the day, myeloma experts will talk about treatments options for newly diagnosed and relapsed/refractory patients, including stem cell transplants, supportive care options, and clinical trials. The specialists will also be available to answer questions. Registration will begin at 9 a.m., and the program will last from 10 a.m. until 3:30 p.m. at the Hamburger University at the Hyatt Lodge. For more information or to register, please see the Multiple Myeloma Research Foundation website.
For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.
News»
According to the results of a Phase 1/2 clinical trial, Torisel in combination with Velcade was well tolerated and effective for the treatment of relapsed/refractory multiple myeloma.
Dr. Irene Ghobrial of the Dana-Farber Cancer Institute presented the results at the 2010 annual American Society of Hematology (ASH) conference held in Orlando last month.
Dr. Ghobrial said the trial results were promising in heavily pretreated myeloma patients and that the combination of Torisel (temsirolimus) and Velcade (bortezomib) warrants further evaluation.
Torisel is marketed by Pfizer and is currently approved for the …
News»
Tuesday was the last day of the American Society of Hematology annual meeting in Orlando. The myeloma portion of the conference concluded with one session of talks in the morning about treatments under development.
The first talk was given by Dr. David Siegel of Hackensack University Medical Center in New Jersey. Dr. Siegel presented results from a study of single-agent carfilzomib in myeloma patients who had relapsed multiple times and did not respond to their last treatment (abstract).
Among the 257 evaluable participants, 24 percent achieved at least a partial …
News»
Preliminary results from an ongoing Phase 2 trial show that a combination therapy of Velcade (bortezomib) and Torisel (temsirolimus) is highly effective in reducing blood and urine levels of abnormal monoclonal protein (known as “M” protein) in multiple myeloma patients. The preliminary study results will be presented at the American Society of Hematology’s (ASH) 51st annual meeting in New Orleans on Monday, December 7.
Myeloma cells produce M proteins. Higher levels of M proteins are directly related to increased disease progression and severity.
Torisel, a drug already approved for use in …
News»
In a recent Phase 2 study, Torisel (temsirolimus) showed little ability to reduce blood and urine levels of abnormal monoclonal protein (known as “M” protein) in relapsed multiple myeloma patients. The results were published in the November issue of the journal Leukemia Research.
Despite recent advancement in treatment options, many myeloma patients relapse and experience disease progression. Therefore, the search continues for new alternatives to treat the disease, especially for patients where previous therapy has proved unsuccessful.
Torisel, a drug already approved for use in advanced renal cell carcinoma, shows potential for …